|
High $0.32 |
Low $0.30 |
Trades 243 |
Turnover $627,825 |
Volume 2,012,212 |
| 30 June 2023 at 4:10pm | ||||
|
Market Cap (14-Nov) $36,843,036 (530th) |
Close (30-Jun) $0.315 |
Volume (30-Jun) 2,012,212 |
Shortsold (9-Nov) 20,215,263 (1.37%) (219th) |
|
52w High $0.470 |
52w Low $0.020 |
P/E 7.20 |
EPS -0.05 |
Appendix 2A
IMM released this announcement to the ASX on 11 December 2020, 17:07. The announcement is not marked as price sensitive, and is 16 page(s) in length and 285.65kb in size.
You can view all announcements from IMM and see how they appear on a price chart on the announcements page.
At the date of this announcement, IMM was 0.046% short sold according to ASIC data. It was ranked the 462nd most shorted stock on the ASX. It is now ranked as the 219th most shorted stock on the ASX with 1.371% of total shares short sold as of the latest reported data (09 November 2026).
| Other Recent Announcements from IMM | |
|---|---|
| Application for quotation of securities - IMM | 29 June 2023, 10:09 |
| US patent granted for Efti with PD-1 pathway inhibitor | 27 June 2023, 14:37 |
| Immutep completes underwritten retail entitlement offer | 27 June 2023, 8:16 |
| Appendix 2A | 11 December 2020, 17:07 |
| Webcast slides for AIPAC Phase IIb breast cancer trial | 11 December 2020, 8:19 |
| Immutep's partner EOC pharma to start Ph II trial in MBC | 10 December 2020, 9:24 |
| Overall Survival data from ph IIb AIPAC breast cancer trial | 10 December 2020, 8:21 |
If you were already registered, log in here.